Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

J Med Chem 2011 Oct 21;54(20):7066-83. Epub 2011 Sep 21.

Novartis Institute for BioMedical Research, CH-4002 Basel, Switzerland.

A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm2006222DOI Listing
October 2011

Publication Analysis

Top Keywords

potent selective
8
factor receptor
8
fibroblast growth
8
growth factor
8
receptor tyrosine
8
models overexpressing
4
substitution pattern
4
pattern aryl
4
designing substitution
4
overexpressing wild-type
4
inhibitors fibroblast
4
selective inhibitors
4
antitumor activity
4
wild-type fgfr3
4
tyrosine kinases
4
xenografts models
4
kinases rationally
4
rationally designing
4
cancer xenografts
4
nvp-bgj398 selected
4

Similar Publications